M.P. Zavelevich1, L.M. Shlapatska1, A.A. Philchenkov1, А.S. Polishchuk1,

N.A Golyarnik2, I.V. Abramenko2, Z.V. Martina2, V.N. Zinchenkо3, D.A. Bazyka2

1R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine,

2National Research Center for Radiation Medicine, NAMS of Ukraine,

3City Clinical Hospital No 9, Kyiv, Ukraine


Summary. Aim: to analyze the expression patterns of CD90, CD117, CD123, and CD147 on cells of the mature B-cell neoplasms, in particular marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) and the expression of CD147 on chronic lymphocytic leukemia (CLL) cells. Object and methods: the expression patterns of the surface antigens on the transformed B cells were analyzed in the peripheral blood samples of the MZL, MCL, and CLL patients (34 patients in total) by the flow cytometry using the monoclonal antibodies. Results: at least one of the antigens – CD90, CD117, or CD123 was expressed in 20.0–33.3% of MCL cases and 27.2–54.5% of MZL cases at the level ≥ 1% of the cells in the subpopulation of CD45-positive lymphoid cells. One MCL case demonstrated the high content of CD117-positive cells (31.0%) accompanied by CD90 expression on 3.8% of cells. The high content of the CD147-positive cells was found not only in MZL and MCL but also in CLL. Conclusion: a small fraction of cells of lymphoid neoplasms expresses several antigens of the leukemic stem cells and cells of the myeloid lineage. The ubiquitous pattern of CD147 expression on cells of these neoplasms has been demonstrated. The diagnostic and prognostic significance of the expression of the studied antigens remains unknown necessitating further clinical studies of the clinical features of these diseases taking into account the expression of the atypical markers.  

Keywords: marginal zone lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, CD90, CD117, CD123, CD147, flow cytometry.



  1. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed, vol 2. Swerdlow S.H., Campo E., Harris N.L., et al. (Eds.). Lyon: IARC; 2017, 585 p.
  2. Philchenkov AA, Zavelevich MP, Abramenko IV, et al. Current state of laboratory diagnosis of mature B-cell lymphoid neoplasms in Ukraine. Oncology (Kyiv) 2022; 24 (3): 184–96. doi: 10.32471/oncology.2663-7928.t-24-3-2022-g.10753 (in Ukrainian).
  3. Desai RH, Zandvakili N, Bohlander SK. Dissecting the genetic and non-genetic heterogeneity of acute myeloid leukemia using next-generation sequencing and in vivo Cancers (Basel) 2022; 14 (9): 2182. doi: 10.3390/cancers14092182.
  4. Kampalath B, Barcos MP, Stewart C, Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol 2003; 119 (6): 824–32. doi: 10.1309/4AGUT3LKEURD7T7K.
  5. Kraj M, Pogłód R, Kopeć-Szlezak J, et al. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies. Leuk Lymphoma 2004; 45 (11): 2281–9. doi: 10.1080/10428190412331283279.
  6. Zimpfer A, Went P, Tzankov A, et al. Rare expression of KIT (CD117) in lymphomas: a tissue microarray study of 1166 cases. Histopathology 2004; 45 (4): 398–404. doi: 10.1111/j.1365-2559.2004.01968.x.
  7. Potti A, Ganti AK, Kargas S, Koch M. Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res 2002; 22 (5): 2899–901. PMID: 12530014.
  8. Vakiani E, Cattoretti G, Colovai AI, et al. CD117 expression in diffuse large B-cell lymphomas: fact or fiction? Pathol Int 2005; 55 (11): 716–23. doi: 10.1111/j.1440-1827.2005.01893.x.
  9. Fromm JR. Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma. Cytometry B Clin Cytom 2011; 80 (2): 91–9. doi: 10.1002/ajh.26390.
  10. Venkataraman G, Aguhar C, Kreitman RJ, et al. Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: Usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders. Am J Clin Pathol 2011; 136 (4): 625–30. doi: 10.1309/AJCPKUM9J4IXCWEU.
  11. Ishiura Y, Kotani N, Yamashita R, et al. Anomalous expression of Thy1 (CD90) in B-cell lymphoma cells and proliferation inhibition by anti-Thy1 antibody treatment. Biochem Biophys Res Commun 2010; 396 (2): 329–34. doi: 10.1016/j.bbrc.2010.04.092.
  12. Zhu D, Wang Z, Zhao JJ, et al. The cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med 2015; 21 (6): 572–80. doi: 10.1038/nm.3867.
  13. Afonso J, Pinto T, Simões-Sousa S, et al. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma. Cell Oncol (Dordr) 2019; 42 (3): 303–18. doi: 10.1007/s13402-019-00426-2.
  14. Liu AG, Hu Q, Tao HF, et al. Expression of CD147 and matrix metalloproteinase-9 in children with non-Hodgkin’s lymphoma and its correlation with prognosis. Zhonghua Er Ke Za Zhi 2009; 47 (10): 785–8.
  15. Shlapatska L, Gordiienko I, Polishchuk A, Gluzman D. Profile of CD150 expression in bone marrow cells of patients with acute myeloid leukemia. Exp Oncol 2022; 44 (3): 198–207. doi: 10.32471/exp-oncology.2312-8852.vol-44-no-3.18307.
  16. Rodriguez CM, Gilardoni MB, Remedi MM, et al. Tumor-stroma interaction increases CD147 expression in neoplastic B lymphocytes in chronic lymphocytic leukemia. Blood Cells Mol Dis 2020; 82: 102405. doi: 10.1016/j.bcmd.2020.102405.
  17. Thorns C, Noack F, Feller AC, et al. Application of newly developed tissue-arrays to study EMMPRIN (CD147) expression in malignant non-Hodgkin lymphoma. Cancer Genomics Proteomics 2004; 1 (1): 45–52.
  18. Peffault de Latour R, Legrand O, Moreau D, et al. Comparison of flow cytometry and enzyme cytochemistry for the detection of myeloperoxydase in acute myeloid leukaemia: Interests of a new positivity threshold. Br J Haematol 2003; 122 (2): 211–6. doi: 10.1046/j.1365-2141.2003.04384.x.

No comments » Add comment